Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

P colucci; J.C. Pottage; H. Robinson; J. Turgeon; D. Schurmann; I.M. Hoepelman; M.P. Ducharme

Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

Translated title of the contribution: Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

P colucci
, J.C. Pottage
, H. Robinson
, J. Turgeon
, D. Schurmann
, I.M. Hoepelman
, M.P. Ducharme

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Original language	Undefined/Unknown
Pages (from-to)	662-669
Number of pages	8
Journal	Antimicrobial Agents and Chemotherapy
Volume	53
Issue number	2
Publication status	Published - 2009

Cite this

colucci, P., Pottage, J. C., Robinson, H., Turgeon, J., Schurmann, D., Hoepelman, I. M., & Ducharme, M. P. (2009). Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrobial Agents and Chemotherapy, 53(2), 662-669.

@article{8fb7df621b2f44b4ab20d6999ba7a5ca,

title = "Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.",

author = "P colucci and J.C. Pottage and H. Robinson and J. Turgeon and D. Schurmann and I.M. Hoepelman and M.P. Ducharme",

year = "2009",

language = "Undefined/Unknown",

volume = "53",

pages = "662--669",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

colucci, P, Pottage, JC, Robinson, H, Turgeon, J, Schurmann, D, Hoepelman, IM & Ducharme, MP 2009, 'Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.', Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 662-669.

Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. / colucci, P; Pottage, J.C.; Robinson, H. et al.
In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 2, 2009, p. 662-669.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.

AU - colucci, P

AU - Pottage, J.C.

AU - Robinson, H.

AU - Turgeon, J.

AU - Schurmann, D.

AU - Hoepelman, I.M.

AU - Ducharme, M.P.

PY - 2009

Y1 - 2009

M3 - Article

SN - 0066-4804

VL - 53

SP - 662

EP - 669

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

ER -